Skip to main content
News

Diabetes Med Recalled


September 09, 2016

Novo Nordisk announced that it is recalling 6 batches of glucagon [rDNA origin] for injection (GlucaGen HypoKit) due to customer complaints.

What was the problem? The complaints, which came from individuals in Portugal and the United Kingdom, involved “detached needles on the syringe with Sterile Water for Injection (SWFI),” the company noted in a statement.

__________________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Antidepressant Recalled
Antibiotic Recalled Due to Iron Oxide Particulates

__________________________________________________________________________________________________________________________________________________________________________

The impacted batches are below.

Batch

Expiration

FS6X270

September 30, 2017

FS6X296

September 30, 2017

FS6X538

September 30, 2017

FS6X597

September 30, 2017

FS6X797

September 30, 2017

FS6X875

September 30, 2017

“It is estimated that out of the 71,215 pens being recalled, 4 pens could be defective,” the company stated.

No adverse events have been reported.

The medication is indicated to treat severe hypoglycemia in patients with diabetes who use insulin, Novo Nordisk noted.

In June, the company launched a recall of Norditropin FlexPro Somatropin (rDNA origin) injection due to defective delivery systems.

 

--Stephanie Vaccaro

 

Reference:

Novo Nordisk Inc. Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit [press release]. www.fda.gov. September 8, 2016.

 

Back to Top